{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T14:51:00Z","timestamp":1785682260424,"version":"3.56.0"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Triple-negative breast cancer (TNBC) patients have an increased risk of developing visceral metastases and other primary nonbreast cancers, particularly lung cancer. The differential diagnosis of TNBC metastases and primary cancers from other organs can be difficult due to lack of a TNBC standard immunoprofile. We analyzed the diagnostic value of estrogen receptor, progesterone receptor, human epidermal growth factor receptor, thyroid transcription factor-1 (TTF1), Napsin A, mammaglobin, gross cystic disease fluid protein 15 (GCDFP15), Sry-related HMg-Box gene 10 (SOX10), GATA-binding protein 3 (GATA3), and androgen receptor in a series of 207 TNBC and 152 primary lung adenocarcinomas (LA). All tested TNBCs were TTF1 and Napsin A-negative. When comparing TNBC and TTF1-positive or negative LA, SOX10 had the best sensitivity (62.3%) and specificity (100%) as a marker in favor of TNBC compared with LA, irrespective of TTF1 status (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001). GATA3 had moderate sensitivity (30.4%) and excellent specificity (98.7%) and misclassified only 2\/152 LA (1.3%). GCDFP15 had a moderate sensitivity (20.8%) and excellent specificity (98%) and misclassified only 3\/152 (2%) LA. Mammaglobin and androgen receptor had moderate sensitivities (38.2% and 30%), good specificities (81.6% and 86%), and misclassified 28\/152 and 21\/152 LAs, respectively. In multivariate analysis, the best markers, enabling the distinction between SOX10-negative TNBC and TTF1 and Napsin A-negative LA were GATA3 (odds ratio=33.5; 95% confidence interval, 7.3-153.5; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001) and GCDFP15 (odds ratio=31.7; 95% confidence interval, 6.9-145.6; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001). Only 13\/207 (6.3%) TNBC cases did not express any aforementioned marker. On the basis of our results, the best sequential immunohistochemical analysis to differentiate TNBC from TTF1-negative LA is first SOX10 followed by GATA3, and finally GCDFP15. This order is important in the diagnostic workup of small biopsies from lung nodules in women with a previous history of TNBC.<\/jats:p>","DOI":"10.1097\/pas.0000000000001216","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T01:51:23Z","timestamp":1547430683000},"page":"293-302","source":"Crossref","is-referenced-by-count":47,"title":["SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Elodie","family":"Laurent","sequence":"first","affiliation":[{"name":"Biopathology"},{"name":"University of Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Begueret","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bonhomme","sequence":"additional","affiliation":[{"name":"Biopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Veillon","sequence":"additional","affiliation":[{"name":"Pneumology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Thumerel","sequence":"additional","affiliation":[{"name":"Thoracic Surgery, University Hospital of Bordeaux, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Velasco","sequence":"additional","affiliation":[{"name":"Biopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Brouste","sequence":"additional","affiliation":[{"name":"Clinical Research and Medical Information"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Clinical Research and Medical Information"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Fournier","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grellety","sequence":"additional","affiliation":[{"name":"Medical Oncology, Institut Bergoni\u00e9, Comprehensive Cancer Centre"},{"name":"University of Bordeaux"},{"name":"INSERM U1218, Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"MacGrogan","sequence":"additional","affiliation":[{"name":"Biopathology"},{"name":"INSERM U1218, Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrclinonc.2016.1","article-title":"Biomarkers of residual disease after neoadjuvant therapy for breast cancer","volume":"13","author":"Penault-Llorca","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10549-011-1564-5","article-title":"Biologic markers determine both the risk and the timing of recurrence in breast cancer","volume":"129","author":"Esserman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mds187","article-title":"Triple-negative breast cancer: epidemiological considerations and recommendations","volume":"23","author":"Boyle","year":"2012","journal-title":"Ann Oncol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","article-title":"Pattern of metastatic spread in triple-negative breast cancer","volume":"115","author":"Dent","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2001.tb01040.x","article-title":"Second primary cancers following breast cancer in the Japanese female population","volume":"92","author":"Tanaka","year":"2001","journal-title":"Jpn J Cancer Res Gann"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0959-8049(97)00173-1","article-title":"Incidence of second primary cancers in three Italian population-based cancer registries","volume":"33","author":"Buiatti","year":"1997","journal-title":"Eur J Cancer"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1054\/bjoc.2000.1603","article-title":"Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England","volume":"84","author":"Evans","year":"2001","journal-title":"Br J Cancer"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2007.11.9081","article-title":"Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study","volume":"26","author":"Schaapveld","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/ijc.21651","article-title":"Risk of second cancer among women with breast cancer","volume":"118","author":"Mellemkjaer","year":"2006","journal-title":"Int J Cancer"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2011-0320-OA","article-title":"Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray","volume":"136","author":"Turner","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2009.06.014","article-title":"Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma","volume":"41","author":"Bishop","year":"2010","journal-title":"Hum Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.09.011","article-title":"GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors","volume":"26","author":"Yang","year":"2017","journal-title":"Ann Diagn Pathol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2559.2012.04344.x","article-title":"Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer","volume":"62","author":"Huo","year":"2013","journal-title":"Histopathology"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/jclinpath-2016-204137","article-title":"Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes","volume":"70","author":"Shaoxian","year":"2017","journal-title":"J Clin Pathol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1309\/TDP92PQLDE2HLEET","article-title":"Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity","volume":"127","author":"Bhargava","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAS.0b013e3182a0218f","article-title":"GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors","volume":"38","author":"Miettinen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1309\/AJCPMFR6OA8ICHNH","article-title":"Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin","volume":"135","author":"Lewis","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/his.13187","article-title":"GATA3 expression in triple-negative breast cancers","volume":"71","author":"Byrne","year":"2017","journal-title":"Histopathology"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.humpath.2012.11.003","article-title":"GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas","volume":"44","author":"Cimino-Mathews","year":"2013","journal-title":"Hum Pathol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1309\/AJCP0Q9UQTEESLHN","article-title":"Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas","volume":"141","author":"Liu","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.humpath.2014.06.022","article-title":"Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer","volume":"45","author":"Krings","year":"2014","journal-title":"Hum Pathol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clbc.2017.01.007","article-title":"Expression profiling of clinical specimens supports the existence of neural progenitor-like stem cells in basal breast cancers","volume":"17","author":"Panaccione","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.2147\/OTT.S126051","article-title":"Targeting the androgen receptor in triple-negative breast cancer: current perspectives","volume":"10","author":"Mina","year":"2017","journal-title":"OncoTargets Ther"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1038\/sj.onc.1208561","article-title":"Identification of molecular apocrine breast tumours by microarray analysis","volume":"24","author":"Farmer","year":"2005","journal-title":"Oncogene"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"R30-20230922","first-page":"1052","article-title":"Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods","volume":"49","author":"Kinsel","year":"1989","journal-title":"Cancer Res"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1200\/JCO.2005.01.7335","article-title":"Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design","volume":"23","author":"Prochazka","year":"2005","journal-title":"J Clin Oncol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10552-012-0054-3","article-title":"The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status","volume":"23","author":"Schonfeld","year":"2012","journal-title":"Cancer Causes Control"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jnci\/86.13.983","article-title":"Lung cancer risk and radiation dose among women treated for breast cancer","volume":"86","author":"Inskip","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.radonc.2016.08.017","article-title":"Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: a systematic review and meta-analysis of population-based studies including 522,739 patients","volume":"121","author":"Grantzau","year":"2016","journal-title":"Radiother Oncol"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canrad.2016.07.101","article-title":"Risks of second malignancies after breast cancer treatment: long-term results","volume":"21","author":"Bazire","year":"2017","journal-title":"Cancer Radiother"},{"key":"R38-20230922","first-page":"99","article-title":"Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas","volume":"3","author":"Wang","year":"1995","journal-title":"Appl Immunohistochem"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.23518","article-title":"How basal are triple-negative breast cancers?","volume":"123","author":"Bertucci","year":"2008","journal-title":"Int J Cancer"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/bcr3035","article-title":"A clinically relevant gene signature in triple negative and basal-like breast cancer","volume":"13","author":"Rody","year":"2011","journal-title":"Breast Cancer Res BCR"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3390\/cancers2021040","article-title":"Biomarkers for basal-like breast cancer","volume":"2","author":"Choo","year":"2010","journal-title":"Cancers"},{"key":"R43-20230922","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R44-20230922","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/modpathol.3800528","article-title":"Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma","volume":"19","author":"Livasy","year":"2006","journal-title":"Mod Pathol"},{"key":"R45-20230922","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/modpathol.2013.97","article-title":"A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard","volume":"26","author":"Won","year":"2013","journal-title":"Mod Pathol"},{"key":"R46-20230922","first-page":"149","article-title":"The development of the normal human breast","volume":"13","author":"Laurence","year":"1991","journal-title":"Oxf Rev Reprod Biol"},{"key":"R48-20230922","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1038\/sj.onc.1206442","article-title":"The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia","volume":"22","author":"Mollaaghababa","year":"2003","journal-title":"Oncogene"},{"key":"R49-20230922","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/bies.20445","article-title":"Sorting out Sox10 functions in neural crest development","volume":"28","author":"Kelsh","year":"2006","journal-title":"BioEssays News Rev Mol Cell Dev Biol"},{"key":"R50-20230922","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1042\/BJ20091237","article-title":"Peroxisome-proliferator-activated receptor-binding protein (PBP) is essential for the growth of active Notch4-immortalized mammary epithelial cells by activating SOX10 expression","volume":"425","author":"Zhu","year":"2009","journal-title":"Biochem J"},{"key":"R51-20230922","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbrc.2017.02.014","article-title":"SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells","volume":"485","author":"Feng","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"R52-20230922","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/PAS.0b013e3181658c14","article-title":"Sox10: a pan-schwannian and melanocytic marker","volume":"32","author":"Nonaka","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R53-20230922","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.humpath.2012.09.005","article-title":"Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas","volume":"44","author":"Cimino-Mathews","year":"2013","journal-title":"Hum Pathol"},{"key":"R54-20230922","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.humpath.2018.06.007","article-title":"Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple negative breast carcinoma","volume":"80","author":"Harbhajanka","year":"2018","journal-title":"Hum Pathol"},{"key":"R55-20230922","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/PAS.0000000000000398","article-title":"Sox10\u2014a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors","volume":"39","author":"Miettinen","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R56-20230922","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.humpath.2017.08.011","article-title":"Utility of Sox10 labeling in metastatic breast carcinomas","volume":"67","author":"Nelson","year":"2017","journal-title":"Hum Pathol"},{"key":"R57-20230922","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncb1530","article-title":"Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation","volume":"9","author":"Asselin-Labat","year":"2007","journal-title":"Nat Cell Biol"},{"key":"R58-20230922","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00000658-197703000-00005","article-title":"Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients","volume":"185","author":"Haagensen","year":"1977","journal-title":"Ann Surg"},{"key":"R59-20230922","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1021\/bi034038a","article-title":"Structural study of GCDFP-15\/gp17 in disease versus physiological conditions using a proteomic approach","volume":"42","author":"Caputo","year":"2003","journal-title":"Biochemistry"},{"key":"R60-20230922","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0046-8177(89)90137-8","article-title":"Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin","volume":"20","author":"Wick","year":"1989","journal-title":"Hum Pathol"},{"key":"R61-20230922","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/PAS.0b013e318157a5a6","article-title":"Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma","volume":"32","author":"Striebel","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R62-20230922","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.humpath.2012.10.009","article-title":"Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas","volume":"44","author":"Luo","year":"2013","journal-title":"Hum Pathol"},{"key":"R63-20230922","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/1471-2407-14-546","article-title":"Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes","volume":"14","author":"Darb-Esfahani","year":"2014","journal-title":"BMC Cancer"},{"key":"R64-20230922","first-page":"135","article-title":"Regulation of GCDFP-15 expression in human mammary cancer cells","volume":"4","author":"Loos","year":"1999","journal-title":"Int J Mol Med"},{"key":"R65-20230922","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/cancers9030021","article-title":"AR signaling in breast cancer","volume":"9","author":"Rahim","year":"2017","journal-title":"Cancers"},{"key":"R66-20230922","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/cancers9010007","article-title":"AR-signaling in human malignancies: prostate cancer and beyond","volume":"9","author":"Schweizer","year":"2017","journal-title":"Cancers"},{"key":"R67-20230922","doi-asserted-by":"crossref","first-page":"82648","DOI":"10.18632\/oncotarget.12244","article-title":"Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex","volume":"7","author":"Berardi","year":"2016","journal-title":"Oncotarget"},{"key":"R68-20230922","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/modpathol.2013.145","article-title":"Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer","volume":"27","author":"Thike","year":"2014","journal-title":"Mod Pathol"},{"key":"R69-20230922","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"R70-20230922","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/modpathol.2009.159","article-title":"Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation","volume":"23","author":"Niemeier","year":"2010","journal-title":"Mod Pathol"},{"key":"R71-20230922","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdp510","article-title":"Expression of androgen receptors in primary breast cancer","volume":"21","author":"Park","year":"2010","journal-title":"Ann Oncol"},{"key":"R72-20230922","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-09-0452","article-title":"Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer","volume":"69","author":"Peters","year":"2009","journal-title":"Cancer Res"},{"key":"R73-20230922","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1002\/1097-0142(19801201)46:11<2463::AID-CNCR2820461127>3.0.CO;2-#","article-title":"Apocrine differentiation in human mammary carcinoma","volume":"46","author":"Mossler","year":"1980","journal-title":"Cancer"},{"key":"R74-20230922","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2174\/1568009043332862","article-title":"Mammaglobin-based strategies for treatment of breast cancer","volume":"4","author":"Goedegebuure","year":"2004","journal-title":"Curr Cancer Drug Targets"},{"key":"R75-20230922","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/modpathol.3800731","article-title":"Breast-specific expression of MGB1\/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers","volume":"20","author":"Sasaki","year":"2007","journal-title":"Mod Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201903000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:45:06Z","timestamp":1695422706000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201903000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001216","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}